A Randomized Controlled Study of Suizenji in Patients with Unresectable Pancreatic Cancer

SONIRE Therapeutics Inc.0 个研究点目标入组 90 人开始时间: 2023年1月31日最近更新: 2025年4月10日

试验速览

暂无简介。

•(1) Ages 20 years and over.
•(2) Unresectable pancreatic cancer (including metastatic pancreatic cancer) who are refractory or intolerant to first-line chemotherapy. Any first-line chemotherapy is acceptable.
•(3) Target treatment tumor is located in the pancreas, and the target tumor can be visualized with ultrasound echography and can also be treated by high-intensity focused ultrasound.
•(4) Has primary tumor site of measurable lesion according to RECIST guidelines version 1.1
•(5) ECOG performance status of 0 to 2.

•(1) Active multiple cancers that require treatment.
•(2) Suspected gastrointestinal invasion of the primary tumor based on CT scan.
•(3) Obstructive jaundice. However, patients who have a bile duct stent placed for obstructive jaundice by the time of allocation may be enrolled.
•(4) Child-Pugh Classification B or C liver failure due to liver metastases.
•(5) Tumor embolization in the veins surrounding the pancreas.
•(6) Cystic component within the pancreatic cancer.
•(7) Peritoneal dissemination.
•(8) Pleural effusion or ascites with poorly controlled
•(9) Contraindications to the use of secondary chemotherapy used in this study.

Overall Survival

未报告次要终点

发起方